HIV/AIDS Topics HIV Treatment
FDA Advisors Favor Approval of 4-in-1 Elvitegravir Quad Pill for HIV
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 11 May 2012 00:00
- Written by Liz Highleyman
On May 11, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval of Gilead Sciences' 4-in-1 once-daily single-tablet antiretroviral regimen known as the Quad. A final decision in expected by late summer.
FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children
- Details
- Category: HIV Treatment
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has approved new dosing recommendations for use of fosamprenavir (Lexiva) oral suspension for children with HIV. The agency also approved a generic nevirapine tablet for use by HIV positive children in PEPFAR countries.
CROI: HIV+ People with CD4 Counts Above 500 Match Life Expectancy of General Population
- Details
- Category: HIV Treatment
- Published on Friday, 13 April 2012 00:00
- Written by Liz Highleyman
People with HIV who respond well to antiretroviral therapy (ART) and achieve undetectable viral load and a CD4 T-cell count above 500 cells/mm3 can have a mortality rate similar to that of HIV negative people, but this is not the case for those with 350-500 cells/mm3, according to a study presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.
HIV Gene Therapy Shows Long-term Safety and Activity after 11 Years
- Details
- Category: Search for a Cure
- Published on Wednesday, 02 May 2012 00:00
- Written by Press Release
Genetically modified T-cells engineered to attack HIV were still present and showed continued antiviral activity, with no serious adverse outcomes, 11 years after administration, according to log-term follow-up data from 3 studies described in the latest issue of Science Translational Medicine.
Novel HIV Integrase Inhibitor Dolutegravir Matches Raltegravir in Phase 3 Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 03 April 2012 00:00
- Written by Press Release
ViiV Healthcare and Japan's Shionogi announced this week that its experimental integrase inhibitor dolutegravir (formerly S/GSK1349572) worked as well as the sole approved integrase inhibitor, raltegravir (Isentress), for people with HIV starting antiretroviral treatment for the first time.
CROI: The Long and Winding Road to a Cure for HIV
- Details
- Category: Search for a Cure
- Published on Friday, 13 April 2012 00:00
- Written by Matt Sharp
No one ever thought finding a cure for AIDS would be easy. Medical research is rarely clear-cut, and an HIV cure breakthrough will be a monumental achievement. Yet at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012), there were significant signs that AIDS cure research is on its way up a long and winding road at the foot of a very big hill. While a functional cure (ability to control HIV without antiretroviral treatment) or total HIV eradication (known as sterilizing cure) may be a steep climb, advances in this field may improve the current state of HIV treatment.
CROI: How Detrimental Is Low but Detectable HIV Viral Load?
- Details
- Category: HIV Treatment
- Published on Tuesday, 03 April 2012 00:00
- Written by Liz Highleyman
Having low but detectable viral load is associated with problems including cardiovascular disease and cancer in people with HIV, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.
More Articles...
- Institute of Medicine Releases Report on Monitoring HIV Care
- New Guidelines: Antiretroviral Therapy and Optimized Care for People with HIV
- Cannabinoids May Inhibit CD4 Cell Infection by CXCR4-tropic HIV
- CROI: San Francisco Early HIV Treatment Policy Linked to Lower Viral Load, Higher CD4 Count
- FDA Approves Etravirine (Intelence) for Children with HIV
